CCCC C4 Therapeutics

C4 Therapeutics to Present at Upcoming Investor Conferences

C4 Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference on Wednesday, May 26, 2021 at 8:00 a.m. ET
  • Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 10:30 a.m. ET

A live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at . Replays of the webcasts will be archived on the C4T website for at least two weeks following the applicable presentation date.

About C4 Therapeutics

C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit .



Investor & Media Contact
Kendra Adams
SVP, Communications & Investor Relations
EN
12/05/2021

Underlying

CCCCC4 Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5...

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the gra...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Bio...

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY. Fireside Chat Details:Date: Wednesday, February 11, 2026 Time: 11:30 AM ET A live webcast will be available on the...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5...

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the gran...

January 26, 2026 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide a...

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways  Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 ...

January 14, 2026 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare C...

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida. Fireside Chat Details:Event: 8th Annual Evercore Healthcare ConferenceDate/Time: Wednesday, December 3rd, 2025 at 3:25 pm ET A ...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch